The Experts below are selected from a list of 8154 Experts worldwide ranked by ideXlab platform
Peter Diem - One of the best experts on this subject based on the ideXlab platform.
-
glycemic control and Macrovascular Disease in types 1 and 2 diabetes mellitus meta analysis of randomized trials
American Heart Journal, 2006Co-Authors: Christoph Stettler, Sabin Allemann, Peter Juni, C A Cull, R R Holman, Matthias Egger, Stephan Krahenbuhl, Peter DiemAbstract:Background Uncertainty persists concerning the effect of improved long-term glycemic control on Macrovascular Disease in diabetes mellitus (DM). Methods We performed a systematic review and meta-analysis of randomized controlled trials comparing interventions to improve glycemic control with conventional treatment in type 1 and type 2 diabetes. Outcomes included the incidence rate ratios for any Macrovascular event, cardiac events, stroke, and peripheral arterial Disease, and the number needed to treat intensively during 10 years to prevent one Macrovascular event. Results The analysis was based on 8 randomized comparisons including 1800 patients with type 1 DM (134 Macrovascular events, 40 cardiac events, 88 peripheral vascular events, 6 cerebrovascular events, 11293 person-years of follow-up) and 6 comparisons including 4472 patients with type 2 DM (1587 Macrovascular events, 1197 cardiac events, 87 peripheral vascular events, 303 cerebrovascular events, 43607 person-years). Combined incidence rate ratios for any Macrovascular event were 0.38 (95% CI 0.26-0.56) in type 1 and 0.81 (0.73-0.91) in type 2 DM. In type 1 DM, effect was mainly based on reduction of cardiac and peripheral vascular events and, in type 2 DM, due to reductions in stroke and peripheral vascular events. Effects appear to be particularly important in younger patients with shorter duration of diabetes. Conclusions Our data suggest that attempts to improve glycemic control reduce the incidence of Macrovascular events both in type 1 and type 2 DM. In absolute terms, benefits are comparable, although effects on specific manifestations of Macrovascular Disease differ.
-
glycemic control and Macrovascular Disease in types 1 and 2 diabetes mellitus meta analysis of randomized trials
American Heart Journal, 2006Co-Authors: Christoph Stettler, Sabin Allemann, Peter Juni, C A Cull, R R Holman, Matthias Egger, Stephan Krahenbuhl, Peter DiemAbstract:Background Uncertainty persists concerning the effect of improved long-term glycemic control on Macrovascular Disease in diabetes mellitus (DM). Methods We performed a systematic review and meta-analysis of randomized controlled trials comparing interventions to improve glycemic control with conventional treatment in type 1 and type 2 diabetes. Outcomes included the incidence rate ratios for any Macrovascular event, cardiac events, stroke, and peripheral arterial Disease, and the number needed to treat intensively during 10 years to prevent one Macrovascular event. Results The analysis was based on 8 randomized comparisons including 1800 patients with type 1 DM (134 Macrovascular events, 40 cardiac events, 88 peripheral vascular events, 6 cerebrovascular events, 11293 person-years of follow-up) and 6 comparisons including 4472 patients with type 2 DM (1587 Macrovascular events, 1197 cardiac events, 87 peripheral vascular events, 303 cerebrovascular events, 43607 person-years). Combined incidence rate ratios for any Macrovascular event were 0.38 (95% CI 0.26-0.56) in type 1 and 0.81 (0.73-0.91) in type 2 DM. In type 1 DM, effect was mainly based on reduction of cardiac and peripheral vascular events and, in type 2 DM, due to reductions in stroke and peripheral vascular events. Effects appear to be particularly important in younger patients with shorter duration of diabetes. Conclusions Our data suggest that attempts to improve glycemic control reduce the incidence of Macrovascular events both in type 1 and type 2 DM. In absolute terms, benefits are comparable, although effects on specific manifestations of Macrovascular Disease differ.
Matthias Egger - One of the best experts on this subject based on the ideXlab platform.
-
glycemic control and Macrovascular Disease in types 1 and 2 diabetes mellitus meta analysis of randomized trials
American Heart Journal, 2006Co-Authors: Christoph Stettler, Sabin Allemann, Peter Juni, C A Cull, R R Holman, Matthias Egger, Stephan Krahenbuhl, Peter DiemAbstract:Background Uncertainty persists concerning the effect of improved long-term glycemic control on Macrovascular Disease in diabetes mellitus (DM). Methods We performed a systematic review and meta-analysis of randomized controlled trials comparing interventions to improve glycemic control with conventional treatment in type 1 and type 2 diabetes. Outcomes included the incidence rate ratios for any Macrovascular event, cardiac events, stroke, and peripheral arterial Disease, and the number needed to treat intensively during 10 years to prevent one Macrovascular event. Results The analysis was based on 8 randomized comparisons including 1800 patients with type 1 DM (134 Macrovascular events, 40 cardiac events, 88 peripheral vascular events, 6 cerebrovascular events, 11293 person-years of follow-up) and 6 comparisons including 4472 patients with type 2 DM (1587 Macrovascular events, 1197 cardiac events, 87 peripheral vascular events, 303 cerebrovascular events, 43607 person-years). Combined incidence rate ratios for any Macrovascular event were 0.38 (95% CI 0.26-0.56) in type 1 and 0.81 (0.73-0.91) in type 2 DM. In type 1 DM, effect was mainly based on reduction of cardiac and peripheral vascular events and, in type 2 DM, due to reductions in stroke and peripheral vascular events. Effects appear to be particularly important in younger patients with shorter duration of diabetes. Conclusions Our data suggest that attempts to improve glycemic control reduce the incidence of Macrovascular events both in type 1 and type 2 DM. In absolute terms, benefits are comparable, although effects on specific manifestations of Macrovascular Disease differ.
-
glycemic control and Macrovascular Disease in types 1 and 2 diabetes mellitus meta analysis of randomized trials
American Heart Journal, 2006Co-Authors: Christoph Stettler, Sabin Allemann, Peter Juni, C A Cull, R R Holman, Matthias Egger, Stephan Krahenbuhl, Peter DiemAbstract:Background Uncertainty persists concerning the effect of improved long-term glycemic control on Macrovascular Disease in diabetes mellitus (DM). Methods We performed a systematic review and meta-analysis of randomized controlled trials comparing interventions to improve glycemic control with conventional treatment in type 1 and type 2 diabetes. Outcomes included the incidence rate ratios for any Macrovascular event, cardiac events, stroke, and peripheral arterial Disease, and the number needed to treat intensively during 10 years to prevent one Macrovascular event. Results The analysis was based on 8 randomized comparisons including 1800 patients with type 1 DM (134 Macrovascular events, 40 cardiac events, 88 peripheral vascular events, 6 cerebrovascular events, 11293 person-years of follow-up) and 6 comparisons including 4472 patients with type 2 DM (1587 Macrovascular events, 1197 cardiac events, 87 peripheral vascular events, 303 cerebrovascular events, 43607 person-years). Combined incidence rate ratios for any Macrovascular event were 0.38 (95% CI 0.26-0.56) in type 1 and 0.81 (0.73-0.91) in type 2 DM. In type 1 DM, effect was mainly based on reduction of cardiac and peripheral vascular events and, in type 2 DM, due to reductions in stroke and peripheral vascular events. Effects appear to be particularly important in younger patients with shorter duration of diabetes. Conclusions Our data suggest that attempts to improve glycemic control reduce the incidence of Macrovascular events both in type 1 and type 2 DM. In absolute terms, benefits are comparable, although effects on specific manifestations of Macrovascular Disease differ.
Peter Juni - One of the best experts on this subject based on the ideXlab platform.
-
glycemic control and Macrovascular Disease in types 1 and 2 diabetes mellitus meta analysis of randomized trials
American Heart Journal, 2006Co-Authors: Christoph Stettler, Sabin Allemann, Peter Juni, C A Cull, R R Holman, Matthias Egger, Stephan Krahenbuhl, Peter DiemAbstract:Background Uncertainty persists concerning the effect of improved long-term glycemic control on Macrovascular Disease in diabetes mellitus (DM). Methods We performed a systematic review and meta-analysis of randomized controlled trials comparing interventions to improve glycemic control with conventional treatment in type 1 and type 2 diabetes. Outcomes included the incidence rate ratios for any Macrovascular event, cardiac events, stroke, and peripheral arterial Disease, and the number needed to treat intensively during 10 years to prevent one Macrovascular event. Results The analysis was based on 8 randomized comparisons including 1800 patients with type 1 DM (134 Macrovascular events, 40 cardiac events, 88 peripheral vascular events, 6 cerebrovascular events, 11293 person-years of follow-up) and 6 comparisons including 4472 patients with type 2 DM (1587 Macrovascular events, 1197 cardiac events, 87 peripheral vascular events, 303 cerebrovascular events, 43607 person-years). Combined incidence rate ratios for any Macrovascular event were 0.38 (95% CI 0.26-0.56) in type 1 and 0.81 (0.73-0.91) in type 2 DM. In type 1 DM, effect was mainly based on reduction of cardiac and peripheral vascular events and, in type 2 DM, due to reductions in stroke and peripheral vascular events. Effects appear to be particularly important in younger patients with shorter duration of diabetes. Conclusions Our data suggest that attempts to improve glycemic control reduce the incidence of Macrovascular events both in type 1 and type 2 DM. In absolute terms, benefits are comparable, although effects on specific manifestations of Macrovascular Disease differ.
-
glycemic control and Macrovascular Disease in types 1 and 2 diabetes mellitus meta analysis of randomized trials
American Heart Journal, 2006Co-Authors: Christoph Stettler, Sabin Allemann, Peter Juni, C A Cull, R R Holman, Matthias Egger, Stephan Krahenbuhl, Peter DiemAbstract:Background Uncertainty persists concerning the effect of improved long-term glycemic control on Macrovascular Disease in diabetes mellitus (DM). Methods We performed a systematic review and meta-analysis of randomized controlled trials comparing interventions to improve glycemic control with conventional treatment in type 1 and type 2 diabetes. Outcomes included the incidence rate ratios for any Macrovascular event, cardiac events, stroke, and peripheral arterial Disease, and the number needed to treat intensively during 10 years to prevent one Macrovascular event. Results The analysis was based on 8 randomized comparisons including 1800 patients with type 1 DM (134 Macrovascular events, 40 cardiac events, 88 peripheral vascular events, 6 cerebrovascular events, 11293 person-years of follow-up) and 6 comparisons including 4472 patients with type 2 DM (1587 Macrovascular events, 1197 cardiac events, 87 peripheral vascular events, 303 cerebrovascular events, 43607 person-years). Combined incidence rate ratios for any Macrovascular event were 0.38 (95% CI 0.26-0.56) in type 1 and 0.81 (0.73-0.91) in type 2 DM. In type 1 DM, effect was mainly based on reduction of cardiac and peripheral vascular events and, in type 2 DM, due to reductions in stroke and peripheral vascular events. Effects appear to be particularly important in younger patients with shorter duration of diabetes. Conclusions Our data suggest that attempts to improve glycemic control reduce the incidence of Macrovascular events both in type 1 and type 2 DM. In absolute terms, benefits are comparable, although effects on specific manifestations of Macrovascular Disease differ.
R R Holman - One of the best experts on this subject based on the ideXlab platform.
-
intensive glucose control and Macrovascular outcomes in type 2 diabetes
Diabetologia, 2009Co-Authors: Fiona Turnbull, Hertzel C Gerstein, R R Holman, William C Duckworth, C Abraira, Robert J Anderson, Robert P Byington, John Chalmers, Gregory W Evans, T MoritzAbstract:Improved glucose control in type 2 diabetes is known to reduce the risk of microvascular events. There is, however, continuing uncertainty about its impact on Macrovascular Disease. The aim of these analyses was to generate more precise estimates of the effects of more-intensive, compared with less-intensive, glucose control on the risk of major cardiovascular events amongst patients with type 2 diabetes. A prospectively planned group-level meta-analysis in which characteristics of trials to be included, outcomes of interest, analyses and subgroup definitions were all pre-specified. A total of 27,049 participants and 2,370 major vascular events contributed to the meta-analyses. Allocation to more-intensive, compared with less-intensive, glucose control reduced the risk of major cardiovascular events by 9% (HR 0.91, 95% CI 0.84–0.99), primarily because of a 15% reduced risk of myocardial infarction (HR 0.85, 95% CI 0.76–0.94). Mortality was not decreased, with non-significant HRs of 1.04 for all-cause mortality (95% CI 0.90–1.20) and 1.10 for cardiovascular death (95% CI 0.84–1.42). Intensively treated participants had significantly more major hypoglycaemic events (HR 2.48, 95% CI 1.91–3.21). Exploratory subgroup analyses suggested the possibility of a differential effect for major cardiovascular events in participants with and without Macrovascular Disease (HR 1.00, 95% CI 0.89–1.13, vs HR 0.84, 95% CI 0.74–0.94, respectively; interaction p = 0.04). Targeting more-intensive glucose lowering modestly reduced major Macrovascular events and increased major hypoglycaemia over 4.4 years in persons with type 2 diabetes. The analyses suggest that glucose-lowering regimens should be tailored to the individual.
-
glycemic control and Macrovascular Disease in types 1 and 2 diabetes mellitus meta analysis of randomized trials
American Heart Journal, 2006Co-Authors: Christoph Stettler, Sabin Allemann, Peter Juni, C A Cull, R R Holman, Matthias Egger, Stephan Krahenbuhl, Peter DiemAbstract:Background Uncertainty persists concerning the effect of improved long-term glycemic control on Macrovascular Disease in diabetes mellitus (DM). Methods We performed a systematic review and meta-analysis of randomized controlled trials comparing interventions to improve glycemic control with conventional treatment in type 1 and type 2 diabetes. Outcomes included the incidence rate ratios for any Macrovascular event, cardiac events, stroke, and peripheral arterial Disease, and the number needed to treat intensively during 10 years to prevent one Macrovascular event. Results The analysis was based on 8 randomized comparisons including 1800 patients with type 1 DM (134 Macrovascular events, 40 cardiac events, 88 peripheral vascular events, 6 cerebrovascular events, 11293 person-years of follow-up) and 6 comparisons including 4472 patients with type 2 DM (1587 Macrovascular events, 1197 cardiac events, 87 peripheral vascular events, 303 cerebrovascular events, 43607 person-years). Combined incidence rate ratios for any Macrovascular event were 0.38 (95% CI 0.26-0.56) in type 1 and 0.81 (0.73-0.91) in type 2 DM. In type 1 DM, effect was mainly based on reduction of cardiac and peripheral vascular events and, in type 2 DM, due to reductions in stroke and peripheral vascular events. Effects appear to be particularly important in younger patients with shorter duration of diabetes. Conclusions Our data suggest that attempts to improve glycemic control reduce the incidence of Macrovascular events both in type 1 and type 2 DM. In absolute terms, benefits are comparable, although effects on specific manifestations of Macrovascular Disease differ.
-
glycemic control and Macrovascular Disease in types 1 and 2 diabetes mellitus meta analysis of randomized trials
American Heart Journal, 2006Co-Authors: Christoph Stettler, Sabin Allemann, Peter Juni, C A Cull, R R Holman, Matthias Egger, Stephan Krahenbuhl, Peter DiemAbstract:Background Uncertainty persists concerning the effect of improved long-term glycemic control on Macrovascular Disease in diabetes mellitus (DM). Methods We performed a systematic review and meta-analysis of randomized controlled trials comparing interventions to improve glycemic control with conventional treatment in type 1 and type 2 diabetes. Outcomes included the incidence rate ratios for any Macrovascular event, cardiac events, stroke, and peripheral arterial Disease, and the number needed to treat intensively during 10 years to prevent one Macrovascular event. Results The analysis was based on 8 randomized comparisons including 1800 patients with type 1 DM (134 Macrovascular events, 40 cardiac events, 88 peripheral vascular events, 6 cerebrovascular events, 11293 person-years of follow-up) and 6 comparisons including 4472 patients with type 2 DM (1587 Macrovascular events, 1197 cardiac events, 87 peripheral vascular events, 303 cerebrovascular events, 43607 person-years). Combined incidence rate ratios for any Macrovascular event were 0.38 (95% CI 0.26-0.56) in type 1 and 0.81 (0.73-0.91) in type 2 DM. In type 1 DM, effect was mainly based on reduction of cardiac and peripheral vascular events and, in type 2 DM, due to reductions in stroke and peripheral vascular events. Effects appear to be particularly important in younger patients with shorter duration of diabetes. Conclusions Our data suggest that attempts to improve glycemic control reduce the incidence of Macrovascular events both in type 1 and type 2 DM. In absolute terms, benefits are comparable, although effects on specific manifestations of Macrovascular Disease differ.
Christoph Stettler - One of the best experts on this subject based on the ideXlab platform.
-
glycemic control and Macrovascular Disease in types 1 and 2 diabetes mellitus meta analysis of randomized trials
American Heart Journal, 2006Co-Authors: Christoph Stettler, Sabin Allemann, Peter Juni, C A Cull, R R Holman, Matthias Egger, Stephan Krahenbuhl, Peter DiemAbstract:Background Uncertainty persists concerning the effect of improved long-term glycemic control on Macrovascular Disease in diabetes mellitus (DM). Methods We performed a systematic review and meta-analysis of randomized controlled trials comparing interventions to improve glycemic control with conventional treatment in type 1 and type 2 diabetes. Outcomes included the incidence rate ratios for any Macrovascular event, cardiac events, stroke, and peripheral arterial Disease, and the number needed to treat intensively during 10 years to prevent one Macrovascular event. Results The analysis was based on 8 randomized comparisons including 1800 patients with type 1 DM (134 Macrovascular events, 40 cardiac events, 88 peripheral vascular events, 6 cerebrovascular events, 11293 person-years of follow-up) and 6 comparisons including 4472 patients with type 2 DM (1587 Macrovascular events, 1197 cardiac events, 87 peripheral vascular events, 303 cerebrovascular events, 43607 person-years). Combined incidence rate ratios for any Macrovascular event were 0.38 (95% CI 0.26-0.56) in type 1 and 0.81 (0.73-0.91) in type 2 DM. In type 1 DM, effect was mainly based on reduction of cardiac and peripheral vascular events and, in type 2 DM, due to reductions in stroke and peripheral vascular events. Effects appear to be particularly important in younger patients with shorter duration of diabetes. Conclusions Our data suggest that attempts to improve glycemic control reduce the incidence of Macrovascular events both in type 1 and type 2 DM. In absolute terms, benefits are comparable, although effects on specific manifestations of Macrovascular Disease differ.
-
glycemic control and Macrovascular Disease in types 1 and 2 diabetes mellitus meta analysis of randomized trials
American Heart Journal, 2006Co-Authors: Christoph Stettler, Sabin Allemann, Peter Juni, C A Cull, R R Holman, Matthias Egger, Stephan Krahenbuhl, Peter DiemAbstract:Background Uncertainty persists concerning the effect of improved long-term glycemic control on Macrovascular Disease in diabetes mellitus (DM). Methods We performed a systematic review and meta-analysis of randomized controlled trials comparing interventions to improve glycemic control with conventional treatment in type 1 and type 2 diabetes. Outcomes included the incidence rate ratios for any Macrovascular event, cardiac events, stroke, and peripheral arterial Disease, and the number needed to treat intensively during 10 years to prevent one Macrovascular event. Results The analysis was based on 8 randomized comparisons including 1800 patients with type 1 DM (134 Macrovascular events, 40 cardiac events, 88 peripheral vascular events, 6 cerebrovascular events, 11293 person-years of follow-up) and 6 comparisons including 4472 patients with type 2 DM (1587 Macrovascular events, 1197 cardiac events, 87 peripheral vascular events, 303 cerebrovascular events, 43607 person-years). Combined incidence rate ratios for any Macrovascular event were 0.38 (95% CI 0.26-0.56) in type 1 and 0.81 (0.73-0.91) in type 2 DM. In type 1 DM, effect was mainly based on reduction of cardiac and peripheral vascular events and, in type 2 DM, due to reductions in stroke and peripheral vascular events. Effects appear to be particularly important in younger patients with shorter duration of diabetes. Conclusions Our data suggest that attempts to improve glycemic control reduce the incidence of Macrovascular events both in type 1 and type 2 DM. In absolute terms, benefits are comparable, although effects on specific manifestations of Macrovascular Disease differ.
